Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

Key Takeaways:

• Xeris Biopharma’s growth plan includes a new Board appointment.
• Menassie M. Taddese offers global commercial leadership and public company governance expertise.
• Xeris Biopharma, traded on Nasdaq as XERS, focuses on endocrine and rare diseases.
• The company aims to enhance patient outcomes by strengthening its leadership team.
• This announcement reflects a positive step in Xeris’s continued expansion.

Xeris Biopharma Expands Leadership

In a recent announcement, Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) welcomed Menassie M. Taddese to its Board of Directors. The company, recognized as a leading endocrine and rare disease biopharmaceutical firm, emphasized Taddese’s strong background in global commercial leadership, financial expertise, and public company governance.

A Step Toward Growth in Endocrine and Rare Diseases

The appointment of Taddese aligns with Xeris Biopharma’s commitment to improving the lives of patients with complex medical conditions. By strengthening its executive team, the company underscores its goal of developing treatments that address significant unmet patient needs in the field of endocrinology and rare diseases.

Adding Financial Expertise and Global Vision

Taddese’s prior experience in finance and leadership positions across the biopharmaceutical sector brings an additional layer of strategic insight to the Board. “We welcome Menassie’s global approach to commercial development, which will be crucial as we expand our operations and deliver on our promise to patients,” the company stated.

Expanding the Mission of Patient Support

A core focus of Xeris Biopharma is to empower patients with endocrine and rare diseases to “realize better lives.” Strengthening its Board with an industry expert is part of a broader effort to enhance its pipeline and improve access to innovative treatments.

Diverse Market Presence

From its listing on the Nasdaq market to its global audience reach in regions such as the United States, Canada, Australia, and beyond, Xeris Biopharma’s leadership decisions resonate across continents. With Taddese on the Board, the company anticipates leveraging his awareness of international markets to further fuel its mission.

The addition of Menassie Taddese signals a disciplined growth trajectory for Xeris Biopharma, ensuring that patients, caregivers, and healthcare professionals worldwide benefit from the organization’s ongoing commitment to innovation and medical advancement.